deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT05093933

A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035) (VICTOR)

A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction

Sponsor: Merck Sharp & Dohme LLC

Conditions Chronic Heart Failure With Reduced Ejection Fraction
Interventions Placebo Vericiguat
Updated 34 times since 2021 Last updated: Dec 4, 2025 Started: Nov 2, 2021 Primary completion: Nov 20, 2024 Completion: Feb 5, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05093933, this PHASE3 trial focuses on Chronic Heart Failure With Reduced Ejection Fraction and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 34 times since 2021, reflecting substantial change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Mar 2024 · 2 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Jan 2025 · 31 days · monthly snapshot~Jan 2025 – ~Mar 2025 · 59 days · monthly snapshot~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – ~Jan 2026 · 2 months · monthly snapshot~Jan 2026 – present · 6 months · monthly snapshot

Change History

34 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE3

  2. Nov 2025 — Jan 2026 [monthly]

    Completed PHASE3

  3. Sep 2025 — Nov 2025 [monthly]

    Completed PHASE3

  4. Mar 2025 — Sep 2025 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. Jan 2025 — Mar 2025 [monthly]

    Active Not Recruiting PHASE3

▶ Show 29 earlier versions

  1. Dec 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Jan 2024 — Mar 2024 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  6. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE3

  7. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE3

  8. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE3

  9. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE3

  10. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE3

  11. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE3

  12. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE3

  13. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE3

  14. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE3

  15. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE3

  16. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE3

  17. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE3

  18. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE3

  19. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE3

  20. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE3

  21. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  22. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE3

  23. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE3

  24. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE3

  25. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE3

  26. Feb 2022 — Mar 2022 [monthly]

    Recruiting PHASE3

  27. Jan 2022 — Feb 2022 [monthly]

    Recruiting PHASE3

  28. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  29. Nov 2021 — Dec 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Aarhus, Denmark , Aberdeen, Hong Kong , Acapulco de Juárez, Mexico , Acaraju, Brazil , Adelaide, Australia , Afyonkarahisar, Turkey (Türkiye) , Aguascalientes, Mexico , Alexander City, United States , Alexandria, United States and 387 more locations